In Japan the incidence of atypical mycobacteriosis has steadily increased, with Mycobacterium avium-intracellulare complex (MAC) the most common infecting organism. A standard chemotherapy regimen for MAC infection has not been established because of significant resistance to anti-mycobacterial drugs. Sparfloxacin has good antimicrobial activity against several acid-fast bacteria and is expected to be an effective drug for treating mycobacteriosis. We examined the effects of adding sparfloxacin to antituberculotic combination therapy in six patients with MAC pulmonary disease.
Introduction
Atypical mycobacteriosis accounts for approximately 15% of cases of acid-fast bacterial infections and its frequency is increasing. 1 More than 50 species of atypical mycobacteria have been identified, and new species appear annually. 1 The most prevalent species in Japan is Mycobacterium avium-intracellulare complex (MAC), followed by M. kansasii, and the proportion of cases of atypical mycobacteriosis due to MAC infection is markedly increasing. MAC has a low pathogenicity in immunocompetent individuals and is not spread by person-to-person contact. Atypical mycobacteria are widely distributed in nature and infection is acquired by environmental exposure to these organisms. Most cases of atypical mycobacteriosis are secondary infections in individuals with chronic lung conditions, particularly those who are middle-aged or elderly.
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Treatment of MAC infection poses difficulties. There is no standard chemotherapeutic regimen, since MAC is highly resistant to anti-mycobacterial drugs compared with other mycobacteria species such as M. tuberculosis and M. kansasii. 1 The American Thoracic Society recommends combination therapy with isoniazid, rifampicin and ethambutol. 2 In recent years, several new drugs, including quinolones and macrolides, have been used in MAC infection, and varying results from in vivo and in vitro studies reported. 3 -7 Sparfloxacin, a pyridone carboxylic acid drug with strong antibacterial activity against several acid-fast bacteria in vitro, is one such candidate expected to be useful as a new therapeutic agent in mycobacteriosis. 3 We examined the antibacterial activity and clinical efficacy of sparfloxacin added to combination therapy with anti-tuberculotic agents in patients with MAC pulmonary disease.
Patients and methods

PATIENTS
Patients with suspected MAC pulmonary disease who visited the Department of Pulmonary
Medicine, Fujita Health University of Medicine and Second Hospital for Medical Education, Nagoya, Japan, or its affiliated hospitals, were enrolled in the study. The study was conducted according to the ethical standards of our medical centre, the Fujita Health University of Medicine, Nagoya. All patients gave informed written consent prior to participation.
CONFIRMATION OF INFECTION
After analysis of the sputum using polymerase chain reaction (PCR) failed to detect the tubercle bacillus, MAC infection was confirmed by culture. This was measured at the first medical examination.
TREATMENT
Combination therapy with anti-tuberculotic agents was initiated as soon as MAC disease was suspected. Patient 1 received 400 mg/day isoniazid, 300/day rifampicin and 750 mg/day ethambutol. Patients 2 -6 received 400 mg/day isoniazid and 450 mg/day rifampicin. 8 Confirmation of diagnosis by incubation and bacterial identification was reached after 1 -3 months. Immediately after confirmation, sparfloxacin was added to the regimen at a dose of 100 mg/day in patients 1 -5 and 200 mg/day in patient 6. In Japan, the recommended dose is 200 mg/day; however, a lower dosage was administered to patients 1 -5 after consideration of their low body weight and medical conditions. The intended treatment period was 6 months, but patients received drug therapy for a period of 1 -8 months, depending on their response. Treatment was discontinued in those patients who were cured. In cases of adverse events, treatment was discontinued after 1 -2 months. End-points of the study were subjective symptoms, chest X-ray findings and bacteriological effect. Subjective symptoms were checked every day. Chest X-ray, sputum samples and blood tests were taken every month. Erythrocyte sedimentation rate (1-h value) was measured once a month. Using a settling pipette, a 1.6 ml blood sample was mixed with 0.4 ml 109 mM sodium acid citrate. The height of the plasma layer in mm (upper portion of the pipette) after 1 h was measured.
The end of the study was defined as confirmed bacteriological eradication. Patients were comprehensively evaluated for improvement in subjective symptoms and chest X-ray. These evaluations were performed when the patient took the drug for the final time. 
DRUG SUSCEPTIBILITY
Mycobacterium avium-intracellulare complex cultured from patient sputum samples was tested for susceptibility to various anti-tuberculotic drugs using the agar dilution method. Briefly, MAC from the sputum samples (taken at the first medical examination) was incubated for 4 weeks at 37°C on Ogawa medium. Half a platinum loopful of the cultured mycobacteria was added to physiological saline to make a 5 ml mycobacterial suspension, and uniform distribution of the suspension produced using a dispersion tube (Kyokuto Seiyaku, Tokyo, Japan). The suspension was diluted 100-fold with Middlebrook 7H9 broth (BD, Franklin Lakes, NJ, USA) to produce a suspension for bacterial inoculation. Middlebrook 7H11 agar plates (BD) containing isoniazid, rifampicin, streptomycin, ethambutol, clarithromycin, and the quinolones sparfloxacin and levofloxacin at various doses (0.025, 0.05, 0.1, 0.2, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50 and 100 µg/ml) were prepared, and 1 µl of suspension was inoculated onto each plate using a replicator. Control samples (Standard MAC strain) were used to check viability.
The plates were incubated for 3 weeks at 37 ºC, and the agar visually inspected for mycobacterial growth. The minimum inhibitory concentration (MIC; the minimum concentration of drug that yielded no bacterial proliferation) and the MIC for 50% (MIC 50 ) and 80% (MIC 80 ) of the isolates were measured using standard methods.
Results
Six patients were included in the study. Four of the patients had underlying diseases: two had inactive tuberculosis, one had chronic pulmonary emphysema, and one had bronchiectasis.
DRUG SUSCEPTIBILITY
The MIC, MIC 50 and MIC 80 for each of the drugs tested are given in Tables 1 and 2 . Fig. 1 shows the accumulated percentages of MIC values for the different concentrations of each drug tested.
CLINICAL AND BACTERIOLOGICAL OUTCOME
The dosing period was 1 -8 months. Sparfloxacin at a dose of 100 mg/day led to bacteriological and clinical improvements in all four patients who completed the study (Table 3) ; these patients tested negative for MAC after 3 -8 months. Two patients (patients 2 and 6) dropped out of the study and treatment was discontinued due to adverse effects. These appeared after 1 month and 2 months of sparfloxacin therapy, respectively, in patients 2 and 6. In both patients the adverse affects were in the form of pruritic skin eruptions, which disappeared immediately after discontinuation of sparfloxacin. The pre-and post-treatment erythrocyte sedimentation rates (ESR) were slightly low in patients 2 and 3.
CASE REPORTS
The clinical courses of two patients are noteworthy.
Patient 1
Patient 1 was an 83-year-old man who complained of coughing and sputum. Analysis of his medical records and family history revealed nothing remarkable. His symptoms first appeared in the middle of October 1998. After taking an over-thecounter medication to no effect, he visited our institute on 9 November 1998. A chest X-ray revealed opacification in the middle and lower fields of the lung. The patient was hospitalized for further investigation and No other haematological or biochemical abnormalities were detected. Tuberculin sensitivity was negative; however, organisms rated as Gaffky 2 were detected in the sputum and pulmonary tuberculosis was suspected. Combination therapy consisting of 400 mg/day isoniazid, 300 mg/day rifampicin and 750 mg/day ethambutol was initiated. When PCR analysis of the patient's sputum was negative for M. tuberculosis and MAC was identified after culture, 100 mg/day sparfloxacin was added to the regimen. The Gaffky test was negative after approximately 3 months' treatment. The patient's symptoms were gradually relieved over the course of the therapy (Fig. 2) . The opacification seen bilaterally in the centre of the middle and lower fields of the lungs on X-ray ( Fig. 3A ) had disappeared after 8 months' therapy ( Fig. 3B ).
Patient 5
Patient 5 was a woman aged 66 years who visited our institute in April 1997 complaining of coughing and mild sputum. Acid-fast bacteria were not detected on a sputum test, but opacification accompanied by cysts was observed in the middle and lower fields of the lung on computed tomography (CT) scanning. A diagnosis of pulmonary tuberculosis was made and a course of anti-mycobacterial drugs initiated. The patient's condition was monitored for 2 months on an out-patient basis. No improvement of symptoms was observed and a further CT scan showed deterioration of the opacification. Bronchoscopy was performed, and organisms rated Gaffky 5 were detected in the bronchoalveolar lavage fluid (BALF). MAC pulmonary disease was diagnosed on the basis of bacterial identification. No abnormal laboratory findings were detected pre-treatment, except for a delayed ESR of 45 mm/h. The CRP level was at the upper end of the normal range, and tuberculin sensitivity was negative. Acid-fast The patient's symptoms improved after 3 months of sparfloxacin therapy, and the BALF was negative for acid-fast bacteria after 6 months of treatment (Fig. 4) . The opacification accompanied by cysts seen bilaterally in the middle lobes of the lungs and in the superior segment of the right lower lobe (Fig. 5A ) improved with treatment, and thinning of the wall in the cyst shadow in the left lingular segment was observed ( Fig. 5B ).
Discussion
The worldwide incidence of atypical mycobacteriosis is increasing, and the infection rate among patients with human immunodeficiency virus disease in Europe and the USA is a serious social issue. 9 The treatment of MAC disease in Japan presents particular difficulties because MAC is highly resistant to anti-mycobacterial drugs. Although discussed by the American College of Clinical Pharmacy in 1985, 10 the Japanese Society for Tuberculosis in 1987 11 and the American Thoracic Society in 1990, 12 a standard chemotherapy for MAC infection has yet to be decided. At present, treatment depends mostly on each physician's accumulated clinical experience. In recent years, combination therapy with new quinolones or macrolides has been studied and varying results have been reported. Berlin et al. 4 demonstrated that clarithromycin has good antibacterial activity against MAC, and Dautzenberg et al. 5 confirmed its clinical efficacy in a controlled randomized trial in 1991. Wallace et al. 6 reported a high efficacy for clarithromycin monotherapy in 1994, and the drug was subsequently approved in the USA. Tomioka et al. 7 have reported that sparfloxacin's anti-MAC activity, both in vivo and in vitro, is equal to that of clarithromycin and slightly higher than that of rifampicin.
We examined the usefulness of adding sparfloxacin to combination therapy with anti-tuberculotic agents in confirmed MAC pulmonary disease. MAC susceptibility to sparfloxacin was equal or superior to that of the other anti-mycobacterial drugs tested, including clarithromycin and levofloxacin, in isolates from all six patients. These results concur with those of others who also reported that sparfloxacin had excellent antibacterial activity against MAC. 3,13 -15 Four of the six patients in our study showed clinical improvement following sparfloxacin therapy, most notably patient 5, in whom the addition of sparfloxacin therapy produced improvement after deterioration 537 was observed during the initial administration of rifampicin, isoniazid and ethambutol. These four patients all tested negative for MAC after 3 -8 months.
Patients 2 and 6 experienced an adverse effect (pruritic skin eruption); this immediately disappeared after discontinuation of therapy with sparfloxacin and was therefore attributed to this drug. Sparfloxacin-induced adverse reactions, especially photosensitization, 16 require particular care, since the course of treatment for mycobacteriosis generally lasts for several months. None of the patients in the present study experienced photosensitization.
Our results suggest that sparfloxacin could be efficacious for treating MAC pulmonary disease, but it should be stressed that clinical efficacy may not always reflect the outcome of susceptibility tests. Saito 17 sparfloxacin is less potent in vivo than in vitro, and another study demonstrated that the pattern of activity of antibacterial drugs is greatly influenced by the type of host cells in which M. tuberculosis and MAC infestation and proliferation have occurred. 18 Further studies of sparfloxacin, including its pharmacokinetics, drug interactions and the chronic toxicities associated with long-term dosing, are required.
